Real-World Experience with a Human Fibrinogen Concentrate: Clinical Data from Adult and Pediatric Patients Requiring Fibrinogen for Bleeding Control and Prevention.
cardiac surgery
hemostasis
human fibrinogen concentrate
hypofibrinogenemia
postpartum hemorrhage
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
03
01
2023
accepted:
01
06
2023
pubmed:
9
6
2023
medline:
9
6
2023
entrez:
9
6
2023
Statut:
ppublish
Résumé
Human fibrinogen concentrate (Fibryga) received temporary approval for fibrinogen replacement therapy in France (2017), with subsequent full approval for congenital and acquired hypofibrinogenemia. We evaluated real-world use for on-demand treatment of bleeding and prophylaxis to enhance our knowledge on fibrinogen concentrate as an option for fibrinogen replacement. Data were retrospectively collected from adult and pediatric patients with fibrinogen deficiency. The primary end point was indication for fibrinogen concentrate use; the secondary end point was treatment success for on-demand treatment/perioperative prophylaxis. The study included 150 adult (median age, 62 years; range, 18-94 years) and 50 pediatric (median age, 3 years; range, 0.01-17 years) patients with acquired fibrinogen deficiency. Fibrinogen concentrate was administered to 47.3% for nonsurgical bleeding, 22.7% for surgical bleeding, and 30.0% for perioperative prophylaxis in adult patients, and to 4.0% for surgical bleeding and 96.0% for perioperative prophylaxis in pediatric patients. Cardiac surgeries accounted for 79.5%/75.0% perioperative prophylaxis and 82.4%/100.0% surgical bleeding cases in adult/pediatric patients, respectively. The mean ± standard deviation (SD, median) total fibrinogen doses were 3.06 ± 1.69 g (32.61 mg/kg), 2.09 ± 1.36 g (22.99 mg/kg), and 2.36 ± 1.25 g (29.67 mg/kg) for adult nonsurgical bleeding, surgical bleeding, and perioperative prophylaxis, respectively; doses of 0.75 ± 0.35 g (47.64 mg/kg) and 0.83 ± 0.62 g (55.56 mg/kg) were used for pediatric surgical bleeding and perioperative prophylaxis, respectively. Treatment success was 85.7%/97.1/93.3% in adults and 50.0%/87.5% in pediatrics for nonsurgical bleeding (adults only), surgical bleeding, and perioperative prophylaxis, respectively. Fibrinogen concentrate demonstrated favorable effectiveness and safety across the age groups. This study contributes to evidence supporting fibrinogen concentrate for bleeding control/prevention in real-world clinical practice, particularly for patients with acquired fibrinogen deficiency.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1186-1196Informations de copyright
© 2023 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2017;37(3):e13-e21.
Alagha S, Songur M, Avci T, et al. Association of preoperative plasma fibrinogen level with postoperative bleeding after on-pump coronary bypass surgery: does plasma fibrinogen level affect the amount of postoperative bleeding? Interact Cardiovasc Thorac Surg. 2018;27(5):671-676.
Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007;5(2):266-273.
Stinger HK, Spinella PC, Perkins JG, et al. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma. 2008;64(2 suppl):S79-85.
Lak M, Keihani M, Elahi F, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol. 1999;107(1):204-206.
Spahn DR, Spahn GH, Stein P. Indications and risks of fibrinogen in surgery and trauma. Semin Thromb Hemost. 2016;42(2):147-154.
Grottke O, Fries D, Nascimento B. Perioperatively acquired disorders of coagulation. Curr Opin Anaesthesiol. 2015;28(2):113-122.
Levy JH, Szlam F, Tanaka KA, et al. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg. 2012;114(2):261-274.
Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23(1):98.
Weber CF, Klages M, Zacharowski K. Perioperative coagulation management during cardiac surgery. Curr Opin Anaesthesiol. 2013;26(1):60-64.
Callum J, Farkouh ME, Scales DC, et al. Effect of fibrinogen concentrate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized clinical trial. JAMA. 2019;322(20):1966-1976.
Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol. 2010;149(6):834-843.
Society for the Advancement of patient Blood Management. Administrative and Clinical Standards for Patient Blood Management Programs. 5th ed. Accessed October 20, 2022. https://sabm.org/wp-content/uploads/SABM-Standards-20196.pdf
Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10(1):23-27.
Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev. 2009;23(3):177-188.
Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth. 2014;113(6):922-934.
Green L, Bolton-Maggs P, Beattie C, et al. British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. Br J Haematol. 2018;181(1):54-67.
Novak A, Stanworth SJ, Curry N. Do we still need cryoprecipitate? Cryoprecipitate and fibrinogen concentrate as treatments for major hemorrhage - how do they compare? Expert Rev Hematol. 2018;11(5):351-360.
Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol. 2017;34(6):332-395.
Chambers LA, Chow SJ, Shaffer LE. Frequency and characteristics of coagulopathy in trauma patients treated with a low- or high-plasma-content massive transfusion protocol. Am J Clin Pathol. 2011;136(3):364-370.
Matsunaga S, Takai Y, Seki H. Fibrinogen for the management of critical obstetric hemorrhage. J Obstet Gynaecol Res. 2019;45(1):13-21.
Seebold JA, Campbell D, Wake E, et al. Targeted fibrinogen concentrate use in severe traumatic haemorrhage. Crit Care Resusc. 2019;21(3):171-178
Boer C, Meesters MI, Milojevic M, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth 2018;32(1):88-120.
Schulz PM, Gehringer W, Nohring S, et al. Biochemical characterization, stability, and pathogen safety of a new fibrinogen concentrate (fibryga®). Biologicals 2018;52:72-77.
U.S. National Library of Medicine. ClinicalTrials.gov. Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data. Accessed October 20, 2022. https://clinicaltrials.gov/ct2/show/NCT04106895?term=NCT04106895&draw=2&rank=1
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3(4):692-694.
Electronic Medicines Compendium. Fibryga 1 g powder and solvent for solution for injection/infusion. Summary of product characteristics. Accessed October 20, 2022. https://www.medicines.org.uk/emc/product/10315/smpc
Černý V, Maegele M, Agostini V, et al. Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting. Eur J Trauma Emerg Surg. 2021:1-12.
Bellon A, Fuseau E, Roumanie O, et al. Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: observed age- and body weight-related differences and consequences for dose adjustment in children. Br J Clin Pharmacol. 2020;86(2):329-337.
Ducloy-Bouthors AS, Mercier FJ, Grouin JM, et al. Early and systematic administration of fibrinogen concentrate in postpartum haemorrhage following vaginal delivery: the FIDEL randomised controlled trial. BJOG. 2021;128(11):1814-1823.
Electronic Medicines Compendium. FibCLOT 1.5 g. Powder and solvent for solution for injection/infusion. Accessed October 20, 2022. https://www.medicines.org.uk/emc/medicine/32987
Collins P, Abdul-Kadir R, Thachil J. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14(1):205-210.
Roy A, Stanford S, Nunn S, et al. Efficacy of fibrinogen concentrate in major abdominal surgery - a prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei. J Thromb Haemost. 2020;18(2):352-363.
Lissitchkov T, Madan B, Djambas Khayat C, et al. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost. 2020;18(4):815-824.
Djambas Khayat C, Lohade S, D'Souza F, et al. Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency. Haemophilia. 2021;27(2):283-292.
Electronic Medicines Compendium. Riastap 1 g Powder for solution for injection/infusion. Accessed July 26, 2022. https://www.medicines.org.uk/emc/product/5909/smpc
Djambas Khayat C, El Khorassani M, Lambert T, et al. Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency. J Thromb Haemost. 2019;17(4):635-644.
Walden K, Jeppsson A, Nasic S, et al. Fibrinogen concentrate to cardiac surgery patients with ongoing bleeding does not increase the risk of thromboembolic complications or death. Thromb Haemost. 2020;120(3):384-391.